FDA Approves New Liquid Formulation of Evoxac Treatment

Adults with Sjögren's disease will soon have a liquid option to help manage dry mouth symptoms.

Updated on Oct. 21, 2026 in Diabetes

Isometric editorial illustration of a single glass vial on a geometric surface, symbolizing medical product development. — The FDA approved a new liquid formulation of Evoxac to aid Sjögren's disease patients in managing symptoms of dry mouth. AI Illustration. Upload story photo >

Live Poll

Do you believe new liquid medication formulations effectively improve daily treatment for chronic conditions?

The FDA has approved a new liquid formulation of Evoxac, designed to help patients with Sjögren's disease manage dry mouth. This alternative delivery method is expected to be available for U.S. patients by the end of 2026.

Why it matters

For patients with Sjögren's disease who struggle with swallowing traditional capsules, this liquid option provides a new way to access symptom relief. It is part of a broader effort to expand treatment delivery options for those managing chronic dryness.

Approval was secured via the FDA 505(b)(2) pathway, which relies on existing safety and efficacy data from the legacy capsule formulation rather than new clinical trials. It remains unclear how the liquid version compares to other supportive therapies in terms of absorption speed.

The players

Cosette Pharmaceuticals

A New Jersey-based company that develops and markets various specialty medications.

Daiichi Sankyo

A global pharmaceutical company that previously marketed the capsule version of Evoxac.

The details

The liquid formulation of Evoxac is designed to assist patients who find swallowing pills difficult, a common challenge in managing Sjögren's disease. The FDA approval process used the 505(b)(2) regulatory pathway, which leverages historical safety data from Daiichi Sankyo's original capsule version. While this assists with dry mouth management, there are currently no FDA-approved medications that treat the underlying autoimmune cause of the condition.

2022: Cosette Pharmaceuticals acquired the rights to Evoxac from Daiichi Sankyo.
October 2026: The FDA officially approved the new liquid formulation of Evoxac.
End of 2026: Cosette Pharmaceuticals expects to launch the liquid oral solution in the U.S. market.

Health Landscape

The approval of a liquid Evoxac formulation utilizes the FDA's 505(b)(2) regulatory pathway to expedite patient access to established medications. This development highlights the current industry trend of pivoting to alternative delivery systems while effective treatments for the autoimmune drivers of Sjögren's disease remain elusive.

If you have been prescribed Evoxac capsules but find them difficult to take, this upcoming liquid formulation may be a more comfortable alternative. You should discuss the suitability of this new oral solution with your primary care provider or rheumatologist closer to the 2026 launch.

The takeaway

While new delivery methods can make daily medication routines easier, they do not change the underlying nature of your condition. Always keep an updated list of your current symptoms and medication challenges to discuss with your doctor during your next visit.